Tag: ACAD
Investors May Want to Use ACADIA Weakness as Opportunity
Don’t write off ACADIA Pharmaceuticals (ACAD) just yet.
In early March, the stock gapped from about $45.50 to $20.63. All after the US FDA rejected...
Subscribe to our mailing list and get interesting stuff and updates to your email inbox.
*by submitting your information you agree to the terms of our Privacy Policy. You will receive FWeekly Stock Watch email and third party offers. You can unsubscribe anytime by selecting unsubscribe at the bottom of our emails.